2 Reasons You Should Love This Biotech's Good News

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The wait is over. Oncologists have been eagerly looking forward to the phase 3 study results for Abraxane in treating pancreatic cancer. On Friday, Swiss biotech Celgene (Nasdaq: CELG  ) ended the anticipation.

What's the verdict? Pancreatic cancer patients taking Abraxane plus Gemzar, developed by Eli Lilly (NYSE: LLY  ) , achieved statistically significant overall survival rates than patients taking Gemzar alone.

Oncologists will love this good news -- and so should you. Here are two reasons why.

1. More hope for patients
Someone you either know or at least know of has died from pancreatic cancer. Steve Jobs, Patrick Swayze, Michael Landon, Luciano Pavarotti, Jack Benny, and Count Basie are just a few well-known people who died from this deadly disease.

Pancreatic cancer ranks as the fourth leading type of cancer. More than 44,000 Americans were diagnosed with it last year, with 37,000 Americans dying from it last year. Only one in 18 patients with pancreatic cancer survives more than five years -- the lowest survival rate of any cancer.

These statistics show that current treatment options such as Gemzar, Roche's Tarceva and Teva Pharmaceuticals' (NYSE: TEVA  ) Adrucil just aren't extremely effective at treating pancreatic cancer. Other experimental drugs haven't fared well, either. Amgen (Nasdaq: AMGN  ) halted its phase 3 clinical trial for ganitumab in August because it didn't prove to be more effective than Gemzar.Threshold Pharmaceuticals (Nasdaq: THLD  ) announced in September that its drug TH-302 failed to improve overall survival rates for pancreatic cancer patients, although TH-302 did improve progression-free survival.

Any good news that gives hope for these patients is news we can all love.

2. More hope for investors
The second reason you should love the good news about Abraxane pales in significance to the first reason. However, I think it is one worth mentioning. The second reason is that investors can find hope in Celgene's news.

Why? Let's face it, the overall market probably won't be all that hot for a while. We've got the so-called fiscal cliff, continued high unemployment, the European financial mess, and CEOs warning of difficulties ahead. Yet there's at least one sector with individual companies that can thrive even in the midst of these challenges. Of course, I'm talking about biotech.

Celgene's announcement epitomizes why biotech investments can be successful despite overall market conditions. Based on the phase 3 results, the company plans to move forward with seeking marketing approvals. The pancreatic cancer market could ultimately generate an additional $1 billion in annual sales worldwide. Considering that Celgene's revenue over the last 12 months was $5.3 billion, that's significant.

More hope ahead
There's reason for more hope ahead.

For pancreatic cancer patients, the hope is that no roadblocks emerge with an expeditious approval of Abraxane. For investors in Celgene, the hope is that Abraxane will gain approval for treating melanoma, that apremilast will be approved for treating psoriatic arthritis and psoriasis, and that pomalidomide will be approved for myeloma.

But for now, good news is, well, good news. Pancreatic cancer patients appear likely to have help on the way. Oncologists might finally have a better treatment to use. Celgene shares jumped nearly 6% in early morning trading. Will the rise continue? I think so. And I hope so.

If you're hoping that you'll find ideas on how to grow your investments, check out our free report "3 Stocks That Will Help You Retire Rich." In this report, we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2107617, ~/Articles/ArticleHandler.aspx, 10/25/2016 8:27:59 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
CELG $97.63 Down -0.44 -0.45%
Celgene CAPS Rating: *****
AMGN $157.90 Down -0.87 -0.54%
Amgen CAPS Rating: ****
LLY $77.75 Up +0.18 +0.23%
Eli Lilly and Co. CAPS Rating: ***
TEVA $43.85 Up +0.35 +0.80%
Teva Pharmaceutica… CAPS Rating: ****
THLD $0.44 Up +0.01 +1.47%
Threshold Pharmace… CAPS Rating: ***